objective To describe the impact and epidemiology of Clostridium difficile infection (CDI) in lowand middle-human development index (LMHDI) countries.
Introduction
Clostridium difficile is an anaerobic, toxin-producing, Gram-positive rod capable of causing infection in healthcare settings and in the community. Initially described in 1935, the association between antibiotic use, pseudomembranous colitis and toxigenic C. difficile has been widely documented [1] [2] [3] . The impact and epidemiology of C. difficile infection (CDI) are now well described as causing considerable morbidity, mortality and healthcare expenditure in high human development index (HHDI) countries [4, 5] . Much less is known about what impact CDI may have in low-and middle-human development index (LMHDI) countries.
Prior antibiotic therapy is one of the greatest risk factors for development of CDI [4] . Antibiotic prescribing practices are closely regulated in many HHDI countries, yet infrequently regulated in LMHDI countries. In many countries, lay-people can purchase antibiotics without healthcare provider's prescription [6] . This perfect storm of unregulated antibiotic use and challenging access to healthcare could lead to spread of C. difficile in these settings. Infection with C. difficile could be particularly devastating as diagnosis of, and therapy for, CDI may not be widely available. Yet despite what should be a favourable environment for the proliferation of C. difficile, in our experience, this infection is infrequently reported in LMHDI settings.
We sought to describe the existing research evaluating CDI in LMHDI countries through a comprehensive and systematic review of existing literature. Our primary goal was to describe existing literature describing CDI in LMHDI countries to establish baseline infection rates, morbidity and mortality associated with CDI.
Methods
We performed a systematic review of existing literatures describing the epidemiology and management of toxigenic C. difficile infection in LMHDI countries. This review was prospectively registered with the Prospero database (Project number 42016036412) in accordance with PRISMA guidelines. PubMed, Ovid and Web of Science databases were searched using the terms 'Clostridium difficile', 'C. difficile', 'antibiotic-associated colitis', 'pseudomembranous colitis' both alone and in combination by country listed by name (Appendix S1). Countries included in the search were those recognised as LMHDI by United Nations Development Programme (UNDP) 2015 as LMHDI [7] . LMHDI designation is a composite index focusing on three dimensions of human development: life expectancy at birth, mean year of schooling and expected years of schooling and gross national income per capita [7] . Inclusion criteria included any randomised, non-randomised, case-control, cohort or demographic studies published between January 2000 and March 2016 so as to obtain the most recent and relevant studies. Studies not written in English were translated using Google Translate and included for further review.
Initial titles and abstracts from all three databases were screened for duplicates and then reviewed for relevance prior to obtaining full-text manuscripts. Eligible articles were independently assessed by blinded reviewers who evaluated each study for pre-established variables. These variables included: study duration, location, type of study, study size, age, gender, comorbid profile, frequency of CDI, grade of infection, community-acquired (CA) or healthcare-associated (HA) infection, toxigenic laboratory diagnosis, strain typing, associated morbidity, mortality and cost of infection. Manuscripts were categorised into observational studies, cohort or case-control studies. Disagreement between reviewers was resolved through discussion with a third reviewer. Exclusion criteria included case reports or abstracts without available full-text articles or studies describing only paediatric patients (defined as patients <18 years of age) or if laboratory confirmation of toxin production was not specified. If studies included fewer than 30 patients, they were not included in quantitative analysis in concordance with the rule of threes sample size based on an assumed infection rate of 10% in these settings. Manuscripts describing studies in unique subpopulations such as immunosuppressed patients were included in the qualitative synthesis but underwent independent subgroup analysis to ensure comparisons between like populations. For studies where subpopulations of patients were described, subgroups were split and considered independently. Missing data were requested from study authors and incorporated when possible. Additional studies were sought by examining the bibliographies of all studies identified during the search process.
Risk factors identified by the Infectious Disease Society of America were compared between studies where this information was available [4] . To be included in the risk factor analysis, a study had to report both the odds ratio and the 95% confidence interval. Due to heterogeneity between studies and risk factors and discrepant definitions, odds ratios were not pooled. Statistical analysis was performed using STATA â (Version 14.1). This was determined to be an IRB exempt study as all articles were publically available.
Results
There were 219 abstracts identified after applying search criteria (Figure 1 ). After duplicate records were removed, 150 abstracts remained. Of these abstracts, 108 were excluded due to non-relevance. Complete manuscripts were obtained for 42 (19% of total) manuscripts, and 17 were excluded for the following reasons: five did not evaluate LMHDI country, four evaluated only a paediatric population, four contained no calculable infection rate or absence of demographic information, three evaluated non-toxin-producing C. difficile and one was an environmental sampling study.
Twenty-five studies met criteria for qualitative synthesis (Table 1 ) . Twenty (80%) were observational studies, three (12%) studies were case-control and two (8%) were cohort studies. Over half (n = 15, 60%) of the studies were conducted in India and seven (28%) were performed in sub-Saharan Africa. Only four (16%) studies were multiinstitution. Most studies (n = 23, 92%) did not define or distinguish between disease severity. Toxigenic status was confirmed solely by enzyme-linked immunosorbent assay (ELISA) in 10 (40%) studies, by toxin assay in eight (32%) studies, by a combination of ELISA and polymerase chain reaction (PCR) in four (16%) studies, by PCR alone in two (8%) studies and by a combination of toxin assay and PCR in one (4%) study. Only one study described the use of surgery as a potential treatment modality for CDI. Eleven (44%) studies reported antecedent antibiotic therapy. Only one (4%) study utilised ribotyping to identify C. difficile strains. One study evaluated only patients with Entamoeba histolytica colitis and one study had less than 30 patients; neither of these studies were included in the quantitative review. No reviewed studies described the financial impact of CDI.
Seventeen studies were used for the quantitative synthesis in the non-immunosuppressed subgroup analysis. Among 10 (59%) studies evaluating symptomatic inpatients, the weighted pooled infection rate was 15.8% (95% confidence interval (CI) 12.1-19.5%). In four (24%) studies evaluating symptomatic patients presenting as outpatients, the weighted pooled infection rate was 10.1 (95% CI 3.0-17.2%). The three (18%) studies that combined inpatients and outpatients had a weighted, pooled infection rate of 10.5% (95% CI 0-33.7%). In the three case-control studies, among controls only five (5%) had evidence of asymptomatic carriage of toxinproducing C. difficile. In the five studies where mortality was reported, there were six fatal cases, which corresponds to a weighted pooled case fatality rate of 18.0% (95% CI 10.0-26.0%).
Among the seven studies describing immunosuppressed patient populations, three described human immunodeficiency virus positive (HIV+) patient populations and two described patients with ulcerative colitis (UC0). One study described CDI after bone marrow transplant, and one study described CDI in patients with psoriatic arthritis. The weighted pooled infection rate among HIV+ patients was 7.4% (95% CI 0-22.8%) and among patients with UC was 15.3% (95% CI 0.0-60.9%). Only one study reported fatal cases, where six deaths were reported among nine cases of CDI in patients who had undergone bone marrow transplant.
Only three (17%) studies described a risk factor analysis (Table 2) . Prior antibiotic use, pharmacologic immunosuppression, prior hospitalisation, intensive care unit admission and tube feeding were associated with increased odds of developing CDI.
Discussion
Clostridium difficile is widely recognised as the most common cause of antibiotic-associated diarrhoea, causes considerable morbidity and mortality, and is a commonly encountered pathogen among surgeons in HHDI countries. Initially described as a healthcare-associated (HA) infection, community-acquired (CA) disease increasingly contributes to the burden of this pathogen [33, 34] . While the human and financial impacts of CDI have been well documented in HHDI, little is known about the burden of this infection in LMHDI countries [35] . To explore existing data describing the impact of CDI in LMHDI countries, we performed a comprehensive, structured literature review. Among symptomatic inpatients, the weighted pooled infection rate among the reviewed manuscripts was 15.8%. Similar studies in HHDI countries have shown rates to be as high as 20-30% [4] . These lower rates in LMHDI settings could be falsely low, and an artefact of underreporting and underdiagnoses. Alternatively, these lower rates in LMHDI settings could be a result of yet undescribed host, environmental, bacterial, microbiome or even cultural factors. Regardless of underlying aetiology, the lower rates of CDI infection among patients in LMHDI countries are encouraging. However, more widespread epidemiologic studies are needed to ensure adequate population sampling, as only three of the 18 studies were multiinstitution studies and none were multinational. To more accurately describe the burden of CDI, a more widespread survey of tertiary referral centres across LMHDI countries could be beneficial.
Less is known about CA-CDI in LMHDI countries. Given the ability of individuals in many LMHDI countries to purchase antibiotics without a prescription, the spread of toxigenic C. difficile could be particularly widespread and problematic [6] . An increasing number of studies are documenting the rise of CA-CDI in HHDI countries, with CA-CDI accounting for up to 32% of CDI cases in some series [33, 34] . In the four studies evaluating symptomatic outpatients, the weighted pooled infection rate was 10.1%. In LMHDI countries where non-C. difficile-related diarrhoeal disease is commonplace and is often treated with antibiotics, the importance of being able to diagnose CDI is critical. Unnecessary antibiotic therapy would be avoided and antibiotic selective pressure could decrease, improving antibiotic stewardship [4] . Among the reviewed studies, the frequency of asymptomatic carriage was 5% which is consistent with prior studies for both asymptomatic carriage and toxin-negative strains both in HHDICs and LMHDICs [36] [37] [38] .
Risk factors for development of CDI in LMHDI countries appear to parallel those found in HHDI countries. Prior antibiotic use -a well-documented risk factor for development of CDI -was found to be associated with increased odds of developing CDI in one of the two studies where this association was explored. However, in most of the studies, pre-infection antibiotic use was documented and frequently predated development of CDI. Only one of two studies evaluating the impact of immunosuppression demonstrated an increased association, specifically among patients who were iatrogenically immunosuppressed through medications. Conversely, among HIV+ patients with diarrhoea the weighted pooled infection rate was 7.4% which was lower than the rate observed in the general non-immunosuppressed patient population. While CDI has been shown to be the most common cause of diarrhoea in HIV patients in HHDICs, this high frequency of CDI among patients living in LMHDICs appears less pronounced [39, 40] . Similarly, UC patients had a weighted pooled infection rate of 15.3% which was the same as symptomatic inpatients in LMHDICs. The association between UC and CDI has been well documented and has been shown to affect younger patients with less prior antibiotic exposure [41] . Notably, two studies, both by Ingle et al. [19, 21] , demonstrated that intensive care unit admission was associated with development of CDI. As both of these two studies occurred at the same institution, it is unclear if the observed increased odds were due to greater risk associated with those authors' institution or if there is widespread increased association with ICU stay and CDI in LMHDI countries. It is also possible that ICU admission is a marker for patients more likely to receive antibiotics or have greater underlying comorbidity.
Few studies described the morbidity and mortality associated with CDI in LMHDI countries. Two studies reported no complications, recurrence or need for surgery among the 249 patients who provided stool samples [19, 21] . The most comprehensive risk factor analysis was performed by Rajabally et al. [9] . In their prospective analysis, seven of 59 patients ultimately required colectomy due to severity of disease. The marked difference in the number of patients requiring surgery for CDI between the Rajabally and Ingle studies underscores the range of CDI-attributable morbidity from the reviewed studies.
There were no estimates assessing the financial burden of CDI in LMHDI countries identified in our review. The total annual CDI-attributable cost to the US is estimated to be $6.3 billion USD [42] and in a meta-analysis incorporating data from other countries, cost of infection was estimated between $8911 to $30 049 USD [35] . Clearly, the opportunity cost of preventing CDI in LMHDI countries outweighs combating an epidemic. However, no baseline cost estimate of CDI in LMHDI countries exists by which to grade prevention interventions.
There are several limitations to this review. First, results reported by each study are difficult to compare given variable definitions of diarrhoea and CDI, and range of utilised laboratory methods. Similarly, the distinction between HA-and CA-CDI was often blurry; patients were usually either stratified as presenting to an outpatient facility or having samples sent from an inpatient facility. Rarely were strict definitions of HA-and CA-CDI provided or followed. Second, few studies were designed for risk factor analysis and, due to variable methods, odds ratios were unable to be pooled limiting the degree to which CDI risk could be attributed to specific risk factors. Third, there is likely selection bias, as only a small number of LMHDI countries were represented in this review. This may limit generalisability of the findings. Fourth, publication bias may be present as institutions may be reticent to publish manuscripts describing patient populations with high rates of CDI infection. These four limitations underscore the need to develop larger consortiums in LMHDI countries to create acceptable case definitions to standardise further investigation.
Conclusions
Despite the marked increase in the understanding the epidemiology of CDI in HHDI countries, there is a paucity of published literature describing the epidemiology and burden of CDI in LMHDI countries. The frequency of CDI among symptomatic inpatients and outpatients appears to be lower in LMHDI countries than in HHDI countries, yet risk factors appear to be broadly similar between these two populations. However, extensive multiinstitutional or multinational studies have not yet been performed. Future epidemiologic studies in LMHDI countries describing basic epidemiology of CDI, risk factors for development of CDI, patient morbidity and mortality, as well as financial burden of infection are urgently needed. Perhaps, the epidemic currently experienced in many HHDI countries might not be repeated in LMHDI countries.
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